Purpose: Patients with Yusho, a condition caused by exposure to dioxins and dioxin-like compounds, have diverse mental and physical complaints. However, the relationship between dioxins and sleep disorders has not yet been examined. This cross-sectional study was designed to investigate problems associated with sleep among patients with Yusho. Methods: A total of 140 participants (52.9% men, average age: 67.1 ± 12.2 years) were examined using questionnaires and medical interviews by an expert on sleep medicine. Demographic and clinical characteristics, including blood concentrations of 2,3,4,7,8-pentachlorodibenzofuran (PeCDF), which is the major cause of Yusho, were obtained from the results of recent surveys conducted by the Yusho Study Group. Results: Moderate to severe symptoms of insomnia were present in 51.8% of the patients. The median Pittsburgh Sleep Quality Index global score (PSQI GS) was 8 (interquartile range: 5-11). The prevalence of restless legs syndrome/Willis-Ekbom disease (RLS/WED) was 30.7%; 24.3% of patients had severe RLS/WED (distressing symptoms with a frequency ≥ 1day per week). A higher blood concentration of 2,3,4,7,8-PeCDF (≥72.27 pg/g lipid) and severe RLS/WED were associated with higher odds of a PSQI GS ≥8, after adjusting for covariates (odds ratio [95% confidence interval]: 4.84 [1.10-21.25] and 4.15 [1.53-11.28], respectively). Conclusions: Symptoms of insomnia were frequent, and the prevalence of RLS/WED was high in patients with Yusho. In addition to the presence of RLS/WED, a higher blood concentration of 2,3,4,7,8-PeCDF was associated with lower subjective sleep quality.
Introduction
In 1968, an outbreak of Yusho, which means "oil disease" in Japanese, occurred in western Japan. This condition was caused by the ingestion of rice bran oil contaminated with polychlorinated biphenyls (PCBs). It was later found that 2,3,4,7,8-pentachlorodibenzofuran (PeCDF) was the main toxic compound among patients with Yusho. Dioxins, such as 2,3,4,7,8-PeCDF and dioxin-like compounds, are generated by the heat denaturation of PCBs. Dioxins are lipophilic and biologically stable in the body. Even now, 50 years after the outbreak, the levels of dioxins are still high in some patients (Mitoma et al., 2015) .
In experimental animals and wildlife, dioxins can be detected in brain samples. After a single administration of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) to rats, TCDD was detected in the brain (Weber et al., 1993) . In dead gulls collected along the coast, TCDD and chloroorganic pesticides can be found in the brain (Falkowska et al., 2016) . Although the transport of dioxins to the central nervous system has not been documented in humans, it can occur in theory.
Dioxins induce a wide variety of biological responses mediated by the aryl hydrocarbon receptor (AHR), which is one of the basic helixloop-helix PER-ARNT-SIM transcription factors. After dioxins and AHR bind in the cytoplasm, AHR translocates to the nucleus and generates a heterodimer with the aryl hydrocarbon receptor translocator (ARNT). The ligand-AHR-ARNT complex binds to a specific promoter region of genes related to xenobiotic metabolism and induces or suppresses the expression of target genes (Wu and Rastinejad, 2016) . AHR and ARNT are expressed in the hypothalamus and in brainstem neurons (Petersen et al., 2000) .
Monoaminergic systems are affected by dioxins through the AHR pathway. Expression of tyrosine hydroxylase (TH), the rate-limiting enzyme for dopamine synthesis, is induced by the administration of TCDD via AHR activation, causing dopamine levels to be increased in vitro (Akahoshi et al., 2009) . After sub-chronic exposure to TCDD, levels of dopamine, norepinephrine, and 5-hydroxy tryptamine are increased in various brain regions of rats (Byers et al., 2006) . Moreover, fetal exposure to TCDD upregulates TH expression in mouse midbrain dopaminergic neurons via the AHR signaling pathway (Tanida et al., 2014) . Monoaminergic systems are active during wakefulness and inactive during sleep (Scammell et al., 2017) . There is concern that chronic dioxin exposure upregulates monoaminergic system activity and disturbs the transition from wakefulness to sleep.
Crosstalk between the AHR pathway and the biological clock system could affect metabolic syndrome through changes in circadian rhythms. AHR activation decreases the amplitude of the expression of circadian clock genes in the suprachiasmatic nucleus (SCN). Conversely, AHR inhibition increases the amplitude of oscillations in the SCN (Jaeger and Tischkau, 2016) . Sleep is achieved through a homeostatic process, which rises during wakefulness, and a circadian process interact with a regulatory mechanism for control of sleep (Borbely, 1982) . The decrease in oscillation amplitude caused by dioxin exposure could affect sleep/wake regulation.
Patients with Yusho have diverse mental and physical complaints. However, the relationship between dioxins and sleep disorders has not yet been examined. This cross-sectional study was designed to investigate problems associated with sleep, including the prevalence and severity of insomnia, sleep disordered breathing (SDB), rapid eye movement sleep behavior disorder (RBD), and restless legs syndrome/ Willis-Ekbom disease (RLS/WED) among patients with Yusho.
Materials and methods

Participants
This study was performed in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Nagasaki University Graduate School of Biomedical Sciences (approval no. 17062109). A total of 275 officially registered patients with Yusho, residents of Goto city (Nagasaki prefecture, Japan) were asked to participate in this study by mail. A total of 140 patients (74 men and 66 women, average age: 67.1 ± 12.2 years) participated in the study. All patients provided written informed consent.
Survey and collection methods
The survey was conducted at Goto city. Data were collected between September 2017 and November 2017. Questionnaires were administered during face-to-face interviews by investigators. Following the interviews, an expert on sleep medicine examined the patients. Medications use, including that of hypnotics, was confirmed in the survey. Screening for SDB was performed over two consecutive nights using a pulse oximeter. Demographic and clinical characteristics, including sex, age, body mass index(BMI), habitual drinking, smoking status, and comorbidities, were obtained from the results of a survey of the current health conditions of officially registered Yusho patients, conducted by the Yusho Study Group in 2016 (Ministry of Health, Labour and Welfare, 2017).
Blood concentrations of 2,3,4,7,8-PeCDF are measured every third year in officially registered Yusho patients. The half-lives of 2,3,4,7,8-PeCDF in the blood of patients with Yusho is reported to be unexpectedly long, and a recent study confirmed prolonged half-lives, particularly patients with high blood concentrations (Matsumoto et al., 2017) . Therefore, the blood concentration of 2,3,4,7,8-PeCDF was obtained from the results of recent surveys conducted by the Yusho Study Group (Katsuki, 2018) . The concentration of 2,3,4,7,8-PeCDF was measured using a solvent-cut large-volume injection system with high-resolution gas chromatography/high-resolution mass spectrometry (Todaka et al., 2003 (Todaka et al., , 2013 . In the diagnostic criteria for Yusho, the following categorization has been made on the basis of the concentration of 2,3,4,7,8-PeCDF in the blood: 1) ≥50 pg/g lipid is an abnormally high concentration; 2) 30-50 pg/g lipid is a moderately elevated concentration, and 3) ≤30 pg/g lipid is a normal concentration (Mitoma et al., 2015) .
Questionnaires
Subjective sleep quality was assessed using the Japanese version of the Pittsburgh Sleep Quality Index (PSQI). The PSQI global score (GS) ranges from 0 to 21, and higher scores indicate worse sleep quality (Buysse et al., 1989) . The severity of insomnia was assessed using the Japanese version of the Insomnia Severity Index (ISI). The severity of difficulty initiating sleep (DIS), difficulty maintaining sleep (DMS) and waking up too early (WE) are answered as "none", "mild", "moderate", "severe", or "very severe". Responders who had "mild" to "very severe" symptoms were defined as having the presence of DIS, DMS, and/or WE. Responders who had "moderate" to "very severe" symptoms were defined as having the presence of moderate to severe DIS, DMS, and/or WE. The global score on this index ranges from 0 to 28, with high scores indicating greater insomnia severity (Bastien et al., 2001) . Daytime sleepiness was assessed using the Japanese version of the Epworth Sleepiness Scale (ESS). The global score on this scale ranges from 0 to 24, with higher scores indicating greater subjective daytime sleepiness (Takegami et al., 2009) .
A Japanese version of the RBD Screening Questionnaire (RBDSQ) was used for the screening of RBD (Miyamoto et al., 2009; StiasnyKolster et al., 2007) . The bed partner's input was encouraged but not required. A Japanese version of the Cambridge-Hopkins questionnaire (CH-RLSq) was used for the screening of RLS/WED (Allen et al., 2009) .
Health-related quality of life was evaluated using the Japanese version of the Short Form-8 (SF8). One item is used to measure each of the eight domains of health, including physical functioning, role limitations because of poor physical health (role physical), bodily pain, general health perception, vitality, social functioning, role limitations due to poor emotional health (role emotional) and mental health. Each SF8 single-item scale can be scored on the same norm-based metrics as the SF36; these scales have a mean of 50 and standard deviation of 10 in the Japanese population (Fukuhara et al., 1998) . Two summary scores, the physical component summary (PCS) and the mental component summary (MCS), were then calculated.
Pulse oximeter
SDB was screened using a pulse oximeter (PULSOX-300i, KONICA MINOLTA Japan, Inc., Tokyo, Japan). The pulse oximeter was attached to the first joint of the second or third fingers on the non-dominant hand at bedtime and removed at the time of awakening over two consecutive nights. The data were downloaded to a personal computer using DS-Me (KONICA MINOLTA Japan, Inc.). After the removal of period of poor measurement, the 3% oxygen desaturation index (ODI) was calculated, defined as the number of times per hour in which the oxygen saturation decreased by 3% or more of the baseline. Patients who had a 3% ODI ≥ 15 or used continuous positive airway pressure were defined as having suspected moderate to severe SDB.
Diagnosis of sleep disorders
RBD could not be diagnosed with certainty since video polysomnography (PSG) was not performed in this study. Therefore, patients suspected of having RBD (suspected RBD) were assessed as having dream-related behaviors or a history of injuries during sleep, even if their RBDSQ score was less than five. Patients who reported sleep talking, continued from childhood, were excluded from the "suspected RBD" classification.
The diagnosis of RLS/WED was based on the 2012 International Restless Legs Syndrome Study Group consensus criteria (Allen et al., 2014 ). An expert on sleep medicine (HK) interviewed the patients to confirm the findings obtained from the CH-RLSq. RLS mimics were carefully excluded. Patients who were suspected of having diabetic peripheral neuropathy were also excluded from the diagnosis of RLS/ WED. Patients who had both a frequency of occurrence ≥1 day per week and distressing symptoms were considered to have severe RLS/ WED.
Statistical analysis
IBM SPSS Statistics version 24 (IBM Corp., Armonk, NY, USA) and R version 3.4.1 were used for statistical analysis. Categorical variables are presented as counts and percentages. Continuous variables are presented as mean and standard deviations where normally distributed, and as median and interquartile range (IQR) where non-normally distributed. Comparisons were made using unpaired t-tests, one-way analysis of variance, with Bonferroni's method for post hoc tests for normally distributed data, Mann-Whitney U tests and the Kruskal-Wallis test for non-normally distributed data, and Fisher's exact test for categorical data. The relationship between continuous variables was investigated by means of Spearman's rank correlation coefficient. The two-sided alpha level was set at 0.05.
Habitual drinkers were defined as people with both a frequency of drinking ≥3 days per week and an alcohol intake ≥20 g of ethanol per day. Hypnotic users were defined as people who were prescribed gamma-aminobutyric acid receptor agonists, melatonin receptor agonists and/or orexin receptor antagonists.
The categorization of subjective sleep quality was dichotomized based on the median of PSQI GS, which was a score of 8. For RBD and RLS/WED, patients were divided into two groups each: suspected RBD and non-suspected RBD, and severe RLS/WED and non-severe RLS/ WED, respectively. For SDB, patients were divided three groups: 3% ODI < 5, 5 ≤ 3% ODI < 15%, and 3% ODI ≥ 15.
The odds ratios for PSQI GS ≥ 8 were calculated using logistic regression analysis to assess the association with dioxin blood concentrations and RSL/WED. Moreover, 2,3,4,7,8-PeCDF blood concentration was categorized based on the following quartiles: first quartile: (Q1 
Results
Prevalence of insomnia symptoms
The prevalence of insomnia symptoms was calculated using the answers from the ISI (Fig. 1) . Three of 140 patients were excluded from the analysis because of missing data on insomnia symptoms. The number of patients who had DIS, DMS, and WE was 74 (54.0%), 89 (65.0%), and 70 (51.1%), respectively. The number of patients who had any one of the three symptoms was 110 (80.3%). The number of patients who had moderate to severe DIS, DMS, and WE was 41 (29.9%), 52 (38.0%) and 46 (33.6%), respectively. The number of patients who had any of the three moderate to severe symptoms was 71 (51.8%).
Prevalence of sleep disorders
Five of 140 patients were excluded from the nocturnal oxygen saturation analysis because of short recording time (less than four hours). The number of patients who had a 3% ODI ≥ 5 was 93 (68.9%). The number of patients who had a 3% ODI ≥ 15 was 24, and two patients had used a continuous positive airway pressure device. A total of 26 patients (18.6%) were suspected of having moderate to severe SBD. RBD was suspected in 23 patients (16.7%), excluding two patients who did not provide adequate answers to the interview. RLS/WED was diagnosed in 43 patients (30.7%). The median (IQR) age of RLS/WED onset was 57.5 (50.0-62.0) years. Except for three patients with juvenile onset, all patients developed RLS/WED after middle age. The number of patients with severe RLS/WED was 34 (24.3%, H. Kondo et al. Environmental Research 166 (2018) [261] [262] [263] [264] [265] [266] [267] [268] 2,3,4,7,8-PeCDF blood concentration and any of the sleep disorders (Supplemental Tables 1, 2 , and 3).
Subjective sleep quality
Valid responses to the PSQI were obtained from 139 of 140 patients. PSQI GS was not normally distributed (Supplemental Fig. 1) . The number of patients who were suspected of being poor sleepers, i.e., those with a PSQI GS ≥ 6, was 92 (71.3%). The median PSQI GS was 8 (IQR, 5-11). Comparisons were made between the PSQI GS < 8 and PSQI GS ≥ 8 groups, and odds ratios for PSQI GS ≥ 8 were calculated.
Compared with patients with a PSQI GS < 8, patients with a PSQI GS ≥ 8 were more likely to be women (p = 0.02), less likely to be habitual drinkers (p = 0.03), and more likely to have a high BMI (p = 0.02). The median 2,3,4,7,8-PeCDF blood concentration among patients with a PSQI GS ≥ 8 was 44.58 (IQR, .83 pg/g lipid), while for patients with a PSQI GS < 8, the median was 22.42 (IQR, .39) pg/g lipid (p = 0.003, Supplemental Fig. 2) . The prevalence of ischemic heart disease, depression, osteoporosis, and severe RLS/WED was significantly higher in patients with a PSQI GS ≥ 8 than in those patients with a PSQI GS < 8 (17.1%, p = 0.009, 10.0%, p = 0.03, 25.7%, p = 0.005% and 35.7%, p = 0.003, respectively), and hypnotic use was more frequent (35.7%, p < 0.001). Concerning the health-related quality of life, the PCS and MCS components of the SF8 were both significantly lower among patients with a PSQI GS ≥ 8 (p = 0.01 and p = 0.007, respectively; Table 2 ).
In a stratified analysis, among patients with a PSQI GS < 8, there was a significant positive correlation between PSQI GS and ESS (Spearman's ρ = 0.259, p = 0.03), but no correlation was found among patients with a PSQI GS ≥ 8. The patients who had been diagnosed with depression or schizophrenia were all women and were included in the group with a PSQI GS ≥ 8, and the median 2,3,4,7,8-PeCDF blood concentration in these patients was quite high, at 102.56 (IQR, 82.14-219.73) pg/g lipid.
The odds ratio of the fourth quartile 2,3,4,7,8-PeCDF blood concentration for PSQI GS ≥ 8 was 4.13 (95% Confidence interval [CI], 1.39-12.27) in a univariate analysis. After adjustment for age, sex, and BMI, the odds ratio was 4.84 (95%CI, 1.10-21.25). The adjusted odds ratio for having severe RLS/WED was 4.15 (95% CI, 1.53-11.28; Table 3 ). No significant association was found between 2,3,4,7,8-PeCDF blood concentration and PSQI GS ≥ 6.
Effect of the 2,3,4,7,8-PeCDF blood concentration
The effect of the 2,3,4,7,8-PeCDF blood concentration on sleep was assessed using categorical data based on quartiles. Patients with a 2,3,4,7,8-PeCDF blood concentration in the fourth quartile were more likely to be women (p < 0.001), have a higher age (p < 0.001), and were less likely to be habitual drinkers (p = 0.02) or to be smokers (p < 0.001). The prevalence of hypertension, depression, and osteoporosis was higher in patients with the fourth quartile 2,3,4,7,8-PeCDF blood concentration than in those in other categories (Table 4) .
Among the symptoms of insomnia, the prevalence of moderate to severe DIS was high in patients with a fourth quartile 2,3,4,7,8-PeCDF blood concentration (53.3%, p = 0.02). The prevalence of DMS and WE did not show statistically significant differences when stratified by the 
Discussion
This is the first clinical study to examine sleep disorders among patients with exposure to high levels of dioxins. The prevalence of insomnia symptoms was high, and that of RLS/WED was extremely high. Notably, high levels of dioxins were associated with lower subjective sleep quality. Even now, 50 years after the outbreak of Yusho, the levels of dioxins are still high in a group of patients with the condition. Clarification of the pathophysiology of sleep disorders caused by exposure to dioxins and adequate medical treatment for the problems associated with sleep disorders among patients with Yusho are needed.
Yusho and insomnia
The prevalence of insomnia symptoms was conspicuously higher among patients with Yusho than in the general population. In the general Japanese adult population, the prevalence of DIS and DMS are 8.6-14.2% and 12.9-18.1% in men and 12.6-20.0% and 16.2-23.4% in women, respectively (Doi et al., 2000; Kaneita et al., 2005) . Approximately 50% of patients with a fourth quartile 2,3,4,7,8-PeCDF blood concentration complained of moderate to severe DIS, and subjective sleep quality was low in this group. Although, the pathophysiological mechanism of sleep disturbance in this study was unclear, the effects of dioxins on the central nervous system, especially the biological clock and sleep/wake systems, should be considered. Moreover, psychiatric disorders and sex differences may have influenced the results of this study.
Although insomnia was severe and the level of dioxin blood concentration was high among patients with a PSQI GS ≥ 8, daytime sleepiness was not increased. This might reflect a hyperarousal state among patients with lower subjective sleep quality. Sub-chronic exposure to dioxin increases the concentration of monoamines in the 18 (60.0) 4 (12.9) < 0.001 Age, years, mean ± SD 59.0 ± 11.1 68.5 ± 10.58 71.7 ± 11.7 74.3 ± 9.6 < 0.001 BMI, kg/m 2 , mean ± SD 23.8 ± 3. 7 (4-10) 6 (5-10) 8 (6-10) 11.0 (7-15) 0.01 ISI, median (IQR) 6 (4-10) 6 (3-11) 6 (3-11) 10 (4-14) 0.41 ESS, median (IQR) 8 (3-9) 4 (2-6) 5 (3-11) 4 (2-6) 0.06 Hypnotics use, n (%) 6 (20.0) 4 (12.9) 5 (16.7) 13 (41.9) 0.04 SDB, n (%) 3% ODI < 5/h 11 (36.7) 8 (27.6) 6 (20. brain (Byers et al., 2006) . Monoaminergic neurons are all active during wakefulness (Scammell et al., 2017) . and activation of these neurons disturbs sleep promotion. Considering that monoaminergic neurons are activated by dioxins through the AHR pathway (Akahoshi et al., 2009; Byers et al., 2006; Tanida et al., 2014) , it is possible that the activity of monoaminergic neuron increases in patients with Yusho. Although circadian rhythm disruptions were not evaluated in this study, it can be assumed that the lower subjective sleep quality resulted from the circadian-disrupting effects of dioxins (Jaeger and Tischkau, 2016) . Patients diagnosed with depression or schizophrenia had a PSQI GS ≥ 8. It has been reported that the severity of depression is associated with higher blood concentrations of polychlorinated biphenyls (PCBs), including dioxin-like compounds (Fitzgerald et al., 2008; Gaum et al., 2014 Gaum et al., , 2017 . A lower concentration in urine homovanillic acid (HVA), one of the metabolites of dopamine, was observed as a surrogate marker of depression and PCBs exposure (Gaum et al., 2017) . Although a causal connection between exposure to dioxins and psychiatric disorders could not be established in this study, the blood concentrations of 2,3,4,7,8-PeCDF were high among patients with depression or schizophrenia; therefore, the effect of dioxins on the central nervous system cannot be ignored.
In this study, the 11 patients with depression or schizophrenia were all women. Moreover, 2,3,4,7,8-PeCDF blood concentrations were found to be significantly higher among the officially registered female Yusho patients than among the male patients (Mitoma et al., 2015) . Among the female patients, the dioxin blood concentration in patients with depression or schizophrenia was quite high. As dioxins are lipophilic, body fat, amounts of sebum, discharge from the Meibomian glands, and red blood cell count are all associated with the sex differences in dioxin blood concentration (Mitoma et al., 2015) .
Yusho and RLS/WED
RLS/WED is frequent among patients with Yusho. The prevalence of RLS/WED in the general adult population is less than 10% in Western countries (Ohayon et al., 2012) , and 1.8% in the Japanese population (Nomura et al., 2008) . Although no control group was considered in this study, a distinctively high prevalence of RLS/WED was found among patients with Yusho. The dioxin blood concentration was not associated with the development of RLS/WED. The reason for this is unclear. However, the onset of RLS/WED and comorbid disease might indicate the pathophysiology of RLS/WED in this group.
In this study, almost all patients with RLD/WED had developed the condition after middle age. It is assumed that the development of RLS/ WED among people with Yusho was caused by acquired factors, including chronic effects of dioxins, rather than by genetic background. Although exposure to dioxin has been shown to increase dopamine synthesis in cell culture and animal studies, sub-chronic exposure to dioxin induces oxidative stress in the central nervous system (Akahoshi et al., 2009; Byers et al., 2006; Tanida et al., 2014) . In a human epidemiological study, a higher blood concentration of PCBs is related to a lower urinary dopamine metabolite HVA (Gaum et al., 2017) . Thus, dioxins might have chronic effects on the central nervous system and induce dysfunction of dopaminergic neurons or neuronal death.
Among the patients with Yusho, osteoporosis was related to lower subjective sleep quality and RLS/WED. Vitamin D deficiency might be a common causal factor for osteoporosis, insomnia, and RLS/WED. Vitamin D has various effects, not only on osteoporosis but also on several other diseases, including mental disorders and metabolic syndrome (Berridge, 2017; Strange et al., 2015; Trinko et al., 2016) . A lower vitamin D blood concentration is related to insomnia and sleep disorders. It is reported that vitamin D deficiency is a predictive factor of poor responsiveness to treatment with hypnotics for chronic insomnia. (Zhao et al., 2017) . RLS/WED is also associated with vitamin D deficiency (Balaban et al., 2012; Prakash et al., 2010) . It has been reported that vitamin D supplementation improves RLS/WED symptoms (Wali et al., 2015) Vitamin D is associated with dopamine synthesis and also with the differentiation of dopaminergic neurons (Cui et al., 2015; Pertile et al., 2016; Trinko et al., 2016) . Moreover, AHR is involved in the synthesis and deactivation of the active form of vitamin D, that is, 1, 25-hyroxy-vitamin D (Matsunawa et al., 2009; Nishimura et al., 2009) . Further studies are needed to clarify the role of vitamin D in patients with Yusho.
Limitations
The study has some limitations. First, the participants were all Yusho patients, and a corresponding group of healthy controls was not considered in this study. The survey was performed in restricted areas, and regional characteristics might have influenced the results of this study. To discuss the prevalence of insomnia symptoms and RLS/WED in this study, reference to the general Japanese adult population was required.
Second, SBD cannot be diagnosed using only a pulse oximeter. The ODI obtained from the pulse oximeter was different from the apneahypopnea index (AHI) obtained from a PSG. As the sleep electroencephalogram was not recorded, the ODI calculated from the pulse oximeter could be lower than the AHI derived from PSG; particularly in the case of insomnia, a lower ODI could be calculated from a longer wakefulness period. Furthermore, in non-obese patients, compared with the AHI derived from PSG, 3% ODI tends to be lower because of mild desaturation (Nakano et al., 2004) . Even though the ODI obtained from the pulse oximeter is low, severe SDB can be observed in some cases. Therefore, the results from the pulse oximeter should be interpreted with caution. PSG is required for the diagnosis of SBD.
Third, PSG with video monitoring is required for the diagnosis of RBD. Although suspected RBD patients were screened in this study using the RBDSQ and interviews with an expert, dream-related behaviors were not always documented. Information from bed partners was obtained for only 47 patients (33.6%). Although the exact prevalence of RBD among patients with Yusho was not clear in this study, some reports have indicated a relationship between dioxins exposure and RBD development. The prevalence of previous occupational pesticide exposure is significantly higher among patients with RBD, and occupational use of pesticides is considered to be one of the environmental risk factors for RBD (Postuma et al., 2012) . Similar findings have been reported for Parkinson's disease (Lai et al., 2002) . Previous exposure to dioxins and dioxin-containing pesticides for workers and residents is a critical issue (Needham et al., 1997) . Video-PSG and other types of neurological examinations should be used to determine if the chronic effects of dioxins are related to the development of RBD.
Fourth, with respect to RLS/WED, peripheral neuropathy was not completely excluded. It has been reported that 20% of Yusho patients are suspected to have peripheral neuropathy (Furuya et al., 2005) . In this study, nerve conduction tests were not performed. Moreover, periodic limb movements, which are supportive of the diagnosis of RLS/ WED, were not assessed because PSG was not performed. Although the responses to dopaminergic agonists provide to these findings, they were not assessed in the current study. A further study is required to evaluate RLS/WED among patients with Yusho.
Fifth, social economic factors and stress affect insomnia. However, in this study, educational background, job status, income, family, and marriage status were not investigated. Additionally, depression was not screened for. The presences of depression or schizophrenia was not included in the logistic regression because of the small number of patients. Further studies with larger sample sizes are needed to clarify the relationship between insomnia and social economic factors or psychiatric disorders.
Conclusions
Symptoms of insomnia were frequent, and moderate to severe H. Kondo et al. Environmental Research 166 (2018) 261-268 insomnia symptoms were observed in approximately 50% of patients with Yusho. Moreover, a notably high prevalence of RLS/WED was found among patients with Yusho. In addition to the presence of RLS/ WED, a higher blood concentration of 2,3,4,7,8-PeCDF was associated with lower subjective sleep quality. Further studies are required to clarify the pathophysiology of sleep disorders caused by exposure to dioxins.
